Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative FLOT phase II trial in resectable esophageal squamous cell carcinoma
jRCTs031200094Phase 2Active, not recruiting
- Start
- Sep 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, oxaliplatin, fluorouracil and folinic acid in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: Histological response rate. Started Sep 2020; status: active, not recruiting.
02
Drugs
docetaxeloxaliplatinfluorouracilfolinic acid
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCTs031200094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200094.